Skip to main content

ORIGINAL RESEARCH article

Front. Oncol., 29 March 2023
Sec. Cancer Imaging and Image-directed Interventions
Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1136366

RETRACTED: A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma

Retracted

A retraction of this article was approved in:

  1. Retraction: A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma

    1. Read retraction
Qing Yang&#x;Qing Yang1†Gengyu Li&#x;Gengyu Li1†Xiaoqiu WuXiaoqiu Wu1Haiying LinHaiying Lin1Wanrui WuWanrui Wu2Xiangpang XieXiangpang Xie2Yu ZhuYu Zhu2Wei CaiWei Cai2Changsheng Shi*Changsheng Shi2*Shengye Zhuo*Shengye Zhuo1*
  • 1Department of Gastroenterology, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
  • 2Interventional vascular Surgery, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

This article has been retracted. Please follow the link to the full retraction notice for details.

Citation: Yang Q, Li G, Wu X, Lin H, Wu W, Xie X, Zhu Y, Cai W, Shi C and Zhuo S (2023) A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma. Front. Oncol. 13:1136366. doi: 10.3389/fonc.2023.1136366

Received: 03 January 2023; Accepted: 20 March 2023;
Published: 29 March 2023; Retracted: 22 February 2024.

Edited by:

Min Tang, Jiangsu University, China

Reviewed by:

Lu Zhang, Biogen Idec, United States
Nian Jiang, University of Tsukuba, Japan

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.